Login|Register|Forget password|Dashboard Back to Home|Contact|Shopcart
Unverified1st Year

QINGDAO BILIN ELECTRICAL APPLIANCES CO., LTD.  

Search
新闻中心
  • 暂无新闻
产品分类
  • 暂无分类
联系方式
  • 联系人:Miss Arissa
  • 电话:86-18661973259
  • 传真:86-532-83182680
站内搜索
 
荣誉资质
  • 暂未上传
友情链接
  • 暂无链接
首页 > Products > Raw Material Favipiravir CAS 259793-96-9 T-705 Avigan for Conoravirus Medicine Cure
Raw Material Favipiravir CAS 259793-96-9 T-705 Avigan for Conoravirus Medicine Cure
单价 面议对比
询价 暂无
浏览 48
发货 Chinashandongqingdao
过期 长期有效
更新 2020-05-06 15:59
 
详细信息
Product Name: Raw Material Favipiravir CAS 259793-96-9 T-705 Avigan for Conoravirus Medicine Cure Purity: >99% State: Solid Suitable for: Elderly, Children, Adult Certification: ISO 9001 Customized: Non-Customized Powder: Yes Origin: China Product Description Raw Material Favipiravir CAS 259793-96-9 T-705 Avigan for Conoravirus Medicine Cure Product nameFavipiravirCAS NO.259793-96-9CategoryPharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.Purity99%Appearanceyellow powderShelf life2 yearsUsageFavipiravir is an antiviral drug.StorageFavipiravir should be stored in a well-closed container at low temperature, keep away from moisture, heat and light.NoteFavipiravir for R&D use only.Favipiravir,alsoknownasT1106,itisapyrazinecarboxamidederivative.Favipiravirisactiveagainstinfluenzaviruses,WestNilevirus,yellowfevervirus,footandmouthdiseasevirusaswellasotherflaviviruses,arenaviruses,bunyavirusesandalphaviruses.ActivityagainstenterovirusesandRiftValleyfevervirushasalsobeendemonstrated.ThemechanismofitsactionsisthoughttoberelatedtotheselectiveinhibitionofviralRNAdependentRNApolymerase.FavipiravirdoesnotinhibitRNAorDNAsynthesisinmammaliancellsandisnottoxictothemIn2014,favipiravirwasapprovedinJapanforstockpilingagainstinfluenzapandemics.EbolavirusdiseaseThedrugappearstobeeffectiveinamousemodelofEbolavirusdisease,butitsefficacyagainsthumanEbolainfectionisunproved.Duringthe2014WestAfricaEbolavirusoutbreak,itwasreportedthataFrenchnursewhocontractedEbolawhilevolunteeringforMSFinLiberiarecoveredafterreceivingacourseoffavipiravir.AclinicaltrialinvestigatingtheuseoffavipiraviragainstEbolavirusdiseasewasstartedinGuéckédou,Guinea,duringDecember2014.PreliminaryresultsshowedadecreaseinmortalityrateinpatientswithlowtomoderatelevelsofEbolavirusintheblood,butnoeffectonpatientswithhighlevelsofthevirus,agroupatahigherriskofdeath.